Novartis AG CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches in the first quarter. He speaks with Bloomberg's Guy Johnson, Kriti Gupta, and Anna Edwards
Novartis AG CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches in the first quarter. He speaks with Bloomberg's Guy Johnson, Kriti Gupta, and Anna Edwards